Core Viewpoint - The research led by Nobel laureate Ardem Patapoutian identifies PIEZO2 as a crucial regulator of renin in the renin-angiotensin-aldosterone system (RAAS), linking it to blood pressure regulation and fluid homeostasis [1][18]. Group 1: Importance of Renin and RAAS - Renin acts as the "start button" for the RAAS, which regulates blood pressure by triggering a series of reactions that lead to vasoconstriction and retention of water and sodium [5]. - The malfunction of this system is closely associated with diseases such as hypertension and heart failure, yet the identity of the pressure sensor in juxtaglomerular cells has remained a mystery for decades [5][19]. Group 2: Identification of PIEZO2 - The research focuses on the PIEZO ion channel family, known for converting mechanical forces into electrochemical signals, with PIEZO2 being abundant in juxtaglomerular cells [7]. - The study confirms that PIEZO2 is likely the long-sought pressure sensor in the kidneys, as its expression is significantly higher in renin-producing cells compared to its counterpart PIEZO1 [7][6]. Group 3: Experimental Findings - Mice lacking PIEZO2 exhibited significantly elevated renin levels, indicating that PIEZO2 functions as a "brake" to prevent excessive renin release under normal conditions [9][8]. - The absence of PIEZO2 disrupted calcium ion oscillations in juxtaglomerular cells, which are essential for regulating renin synthesis and release [11][10]. Group 4: Impact on Renal Function - Mice without PIEZO2 showed increased glomerular filtration rates, likely due to elevated renin activating the ACE2/Ang(1-7)/MAS compensatory pathway, which dilates blood vessels [14][13]. - The study highlights PIEZO2's role as a "faithful sentinel" of blood volume, effectively regulating renin release in response to changes in blood pressure [16][15]. Group 5: Scientific and Clinical Implications - This research resolves a fundamental physiological question regarding renal pressure sensing and establishes a link between PIEZO channels and the RAAS [18][19]. - The findings provide new insights into the pathophysiology of hypertension and heart failure, suggesting that targeting PIEZO2 could lead to novel treatments for cardiovascular and renal diseases [20].